Novel immunomodulatory drugs and neo-substrates

Selective inhibition of BET bromodomains

Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · see citing works

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575 · see citing works

Thalidomide is an inhibitor of angiogenesis.

D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454 · see citing works

Identification of a Primary Target of Thalidomide Teratogenicity

Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136 · see citing works

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879 · see citing works

Phthalimide conjugation as a strategy for in vivo target protein degradation

Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760 · see citing works

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583 · see citing works

Induced protein degradation: an emerging drug discovery paradigm

Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486 · see citing works

Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450 · see citing works

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445 · see citing works

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319 · see citing works

Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide

Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141 · see citing works

Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4

Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056 · see citing works

Thalidomide-induced Teratogenesis: History and Mechanisms

Vargesson, N. (2015) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.21096 · Cited by 912 · see citing works

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

Davies, F. E., Raje, N. S., Hideshima, T., Lentzsch, S., Young, G. Q., Tai, Y., Lin, B. K., Podar, K., Gupta, D., Chauhan, D., et al. (2001) · Blood · doi:10.1182/blood.v98.1.210 · Cited by 912 · see citing works

Efficacy of Lenalidomide in Myelodysplastic Syndromes

List, A., Kurtin, S., Roe, D. J., Buresh, A., Mahadevan, D., Fuchs, D., Rimsza, L., Heaton, R., Knight, R., & Zeldis, J. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041668 · Cited by 880 · see citing works

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS

Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature · doi:10.1038/nature14610 · Cited by 863 · see citing works

A short history of thalidomide embryopathy

Lenz, W. (1988) · Teratology · doi:10.1002/tera.1420380303 · Cited by 786 · see citing works

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.

Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L. M., Ocampo, C. J., Patterson, R. T., Stirling, D., & Kaplan, G. (1999) · PubMed · Cited by 729 · see citing works

A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase

Matyskiela, M. E., Lu, G., Ito, T., Pagarigan, B., Lu, C.-C., Miller, K., Fang, W., Wang, N.-Y., Nguyen, D., Houston, J., et al. (2016) · Nature · doi:10.1038/nature18611 · Cited by 701 · see citing works

Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That Are Potent Inhibitors of TNF-α

Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L.-M., Ocampo, C. J., Patterson, R. T., Stirling, D., & Kaplan, G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.380 · Cited by 654 · see citing works

Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase

Petzold, G., Fischer, E. S., & Thomä, N. H. (2016) · Nature · doi:10.1038/nature16979 · Cited by 620 · see citing works

Modular PROTAC design for the degradation of oncogenic BCR-ABL

Lai, A. C., Toure, M., Hellerschmied, D., Salami, J., Jaime‐Figueroa, S., Ko, E., Hines, J., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507634 · Cited by 618 · see citing works

Engineering CAR-T cells

Zhang, C., Liu, J., Zhong, J. F., & Zhang, X. (2017) · Biomarker Research · doi:10.1186/s40364-017-0102-y · Cited by 578 · see citing works

Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation

Guedan, S., Posey, A. D., Shaw, C. E., Wing, A., Da, T., Patel, P. R., McGettigan, S. E., Casado‐Medrano, V., Kawalekar, O. U., Uribe‐Herranz, M., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96976 · Cited by 577 · see citing works

Thalidomide Costimulates Primary Human T Lymphocytes, Preferentially Inducing Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8+ Subset

Haslett, P. A. J., Corral, L. G., Albert, M. L., & Kaplan, G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.11.1885 · Cited by 572 · see citing works

Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation

Olson, C. M., Jiang, B., Erb, M. A., Liang, Y., Doctor, Z. M., Zhang, Z., Zhang, T., Kwiatkowski, N., Boukhali, M., Green, J. L., et al. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2538 · Cited by 552 · see citing works

Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN

Sievers, Q. L., Petzold, G., Bunker, R. D., Renneville, A., Słabicki, M., Liddicoat, B. J., Abdulrahman, W., Mikkelsen, T., Ebert, B. L., & Thomä, N. H. (2018) · Science · doi:10.1126/science.aat0572 · Cited by 537 · see citing works

Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs

Chamberlain, P. P., Lopez-Girona, A., Miller, K., Carmel, G., Pagarigan, B., Chie-Leon, B., Rychak, E., Corral, L. G., Ren, Y. J., Wang, M., et al. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2874 · Cited by 531 · see citing works

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

Zhao, W., Liu, J., Wang, B., Chen, Y., Cao, X.-M., Yang, Y., Zhang, Y., Wang, F., Zhang, P., Lei, B., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0681-6 · Cited by 520 · see citing works

Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome

Donovan, K. A., An, J., Nowak, R. P., Yuan, J. C., Fink, E. C., Berry, B. C., Ebert, B. L., & Fischer, E. S. (2018) · eLife · doi:10.7554/elife.38430 · Cited by 509 · see citing works

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

Fenaux, P., Giagounidis, A. A. N., Selleslag, D., Beyne‐Rauzy, O., Mufti, G. J., Mittelman, M., Muus, P., Boekhorst, P. A. W. T., Sanz, G. F., del Cañizo, C., et al. (2011) · Blood · doi:10.1182/blood-2011-01-330126 · Cited by 488 · see citing works

Delineating the role of cooperativity in the design of potent PROTACs for BTK

Zorba, A., Nguyen, C., Xu, Y., Starr, J., Borzilleri, K., Smith, J., Zhu, H., Farley, K. A., Ding, W., Schiemer, J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803662115 · Cited by 419 · see citing works

Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study

Chanan-Khan, A. A., Miller, K. C., Musial, L., Lawrence, D. D., Padmanabhan, S., Takeshita, K., Porter, C. W., Goodrich, D. W., Bernstein, Z. P., Wallace, P. K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.0401 · Cited by 414 · see citing works

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

Ferrajoli, A., Lee, B.-N., Schlette, E. J., O'Brien, S. M., Gao, H., Wen, S., Wierda, W. G., Estrov, Z. E., Faderl, S., Cohen, E. N., et al. (2008) · Blood · doi:10.1182/blood-2007-12-130120 · Cited by 405 · see citing works

Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs

An, S., & Fu, L. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.005 · Cited by 363 · see citing works

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel

Caers, J., Paiva, B., Zamagni, E., Leleu, X. P., Bladé, J., Kristinsson, S. Y., Touzeau, C., Abildgaard, N., Terpos, E., Heusschen, R., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0549-1 · Cited by 338 · see citing works

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application

Hayashi, T., Hideshima, T., Akiyama, M., Podar, K., Yasui, H., Raje, N. S., Kumar, S. K., Chauhan, D., Treon, S. P., Richardson, P. G. G., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05286.x · Cited by 323 · see citing works

Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma

Schey, S., Fields, P. A., Bartlett, J. B., Clarke, I., Ashan, G., Knight, R., Streetly, M. J., & Dalgleish, A. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.052 · Cited by 312 · see citing works

A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos

Matyskiela, M. E., Zhang, W., Man, H.-W., Muller, G., Khambatta, G., Baculi, F., Hickman, M., LeBrun, L., Pagarigan, B., Carmel, G., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01921 · Cited by 309 · see citing works

Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals)

Schiedel, M., Herp, D., Hammelmann, S., Swyter, S., Lehotzky, A., Robaa, D., Oláh, J., Ovádi, J., Sippl, W., & Jung, M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01872 · Cited by 275 · see citing works

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

Habermann, T. M., Lossos, I. S., Justice, G. R., Vose, J. M., Wiernik, P. H., McBride, K., Wride, K., Ervin-Haynes, A. L., Takeshita, K., PIETRONIGRO, D. D., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07626.x · Cited by 244 · see citing works

Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)

Zhang, C., Han, X.-R., Yang, X., Jiang, B., Liu, J., Xiong, Y., & Jin, J. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.071 · Cited by 226 · see citing works

Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)

Robb, C. M., Contreras, J. I., Kour, S., Taylor, M., Abid, M., Sonawane, Y. A., Zahid, M., Murry, D. J., Natarajan, A., & Rana, S. (2017) · Chemical Communications · doi:10.1039/c7cc03879h · Cited by 221 · see citing works

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

Hagner, P. R., Man, H.-W., Fontanillo, C., Wang, M., Couto, S., Breider, M., Bjorklund, C., Havens, C. G., Lu, G., Rychak, E., et al. (2015) · Blood · doi:10.1182/blood-2015-02-628669 · Cited by 203 · see citing works

THALIDOMIDE AND CONGENITAL ABNORMALITIES

Somers, G. F. (1962) · The Lancet · doi:10.1016/s0140-6736(62)91943-8 · Cited by 201 · see citing works

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma

Garfall, A. L., Stadtmauer, E. A., Hwang, W., Lacey, S. F., Melenhorst, J. J., Krevvata, M., Carroll, M. P., Matsui, W. H., Wang, Q., Dhodapkar, M. V., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120505 · Cited by 196 · see citing works

THALIDOMIDE AND CONGENITAL ABNORMALITIES

Speirs, A. L. (1962) · The Lancet · doi:10.1016/s0140-6736(62)91248-5 · Cited by 179 · see citing works

pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase

An, J., Ponthier, C. M., Sack, R., Seebacher, J., Stadler, M. B., Donovan, K. A., & Fischer, E. S. (2017) · Nature Communications · doi:10.1038/ncomms15398 · Cited by 176 · see citing works

Drugs and the heart. V. Digitalis and sympathomimetic stimulants.

Opie, L. H. (1980) · PubMed · Cited by 172 · see citing works

Homo-PROTACs for the Chemical Knockdown of Cereblon

Steinebach, C., Lindner, S., Udeshi, N. D., Mani, D. R., Kehm, H., Köpff, S., Carr, S. A., Gütschow, M., & Krönke, J. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00693 · Cited by 160 · see citing works

Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Badoux, X. C., Keating, M. J., Wen, S., Wierda, W. G., O'Brien, S. M., Faderl, S., Sargent, R., Burger, J. A., & Ferrajoli, A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8623 · Cited by 158 · see citing works

Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands

Shibata, N., Nagai, K., Morita, Y., Ujikawa, O., Ohoka, N., Hattori, T., Koyama, R., Sano, O., Imaeda, Y., Nara, H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00168 · Cited by 147 · see citing works

How Thalidomide Works Against Cancer

Stewart, A. K. (2014) · Science · doi:10.1126/science.1249543 · Cited by 125 · see citing works

Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma

Ruan, J., Martin, P., Christos, P. J., Cerchietti, L. C. A., Tam, W., Shah, B. D., Schuster, S. J., Rodriguez, A., Hyman, D. M., Calvo-Vidal, M. N., et al. (2018) · Blood · doi:10.1182/blood-2018-07-859769 · Cited by 124 · see citing works

Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study

Zinzani, P. L., Vose, J. M., Czuczman, M. S., Reeder, C. B., Haïoun, C., Polikoff, J. A., Tilly, H., Zhang, L. F., Prandi, K., Li, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt366 · Cited by 120 · see citing works

Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing

Li, Z., Song, W., Rubinstein, M. P., & Liu, D. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0684-3 · Cited by 118 · see citing works

Engineering switchable and programmable universal CARs for CAR T therapy

Liu, D., Zhao, J., & Song, Y. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0763-0 · Cited by 113 · see citing works

Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia

Zhao, J., Song, Y., & Liu, D. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0705-x · Cited by 109 · see citing works

A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies

Rasco, D. W., Papadopoulos, K. P., Pourdehnad, M., Gandhi, A. K., Hagner, P. R., Li, Y., Wei, X., Chopra, R., Hege, K. M., DiMartino, J. F., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1203 · Cited by 94 · see citing works

HEAD INJURY AND ADMISSION POLICY

Jennett, B., & Galbraith, S. (1979) · The Lancet · doi:10.1016/s0140-6736(79)90970-x · Cited by 85 · see citing works

A Mini-Review on Thalidomide: Chemistry, Mechanisms of Action, Therapeutic Potential and Anti-Angiogenic Properties in Multiple Myeloma

Mercurio, A., Adriani, G., Catalano, A. A., Carocci, A., Rao, L., Lentini, G., Cavalluzzi, M. M., Franchini, C., Vacca, A., & Corbo, F. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170601074646 · Cited by 83 · see citing works

Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus

Schafer, P. H., Ye, Y., Wu, L., Kosek, J., Ringheim, G., Yang, Z., Liu, L., Thomas, M., Palmisano, M., & Chopra, R. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212916 · Cited by 78 · see citing works

NF-κB signaling and its relevance to the treatment of mantle cell lymphoma

Balaji, S., Ahmed, M., Lorence, E., Yan, F., Nomie, K. J., & Wang, M. L. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0621-5 · Cited by 77 · see citing works

Deficiency of immunoregulatory indoleamine 2,3-dioxygenase 1 in juvenile diabetes

Orabona, C., Mondanelli, G., Pallotta, M. T., Carvalho, A., Albini, E., Fallarino, F., Vacca, C., Volpi, C., Belladonna, M. L., Berioli, M. G., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96244 · Cited by 75 · see citing works

Proteolysis-Targeting Chimeras: Harnessing the Ubiquitin-Proteasome System to Induce Degradation of Specific Target Proteins

Coleman, K. G., & Crews, C. M. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050430 · Cited by 66 · see citing works

Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma

Xu, J., Wang, Q., Xu, H., Gu, C., Jiang, L., Wang, J., Wang, D., Xu, B., Mao, X., Wang, J., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0672-7 · Cited by 62 · see citing works

Lenalidomide and dexamethasone for multiple myeloma

Naunton, M. (2013) · Journal of Pharmacy Practice and Research · Cited by 49 · see citing works

Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study

Dimopoulos, M. A., Wang, M. L., Maisnar, V., Minařík, J., Bensinger, W., Mateos, M., Obreja, M., Blædel, J., & Moreau, P. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0583-7 · Cited by 46 · see citing works

Mantle cell lymphoma and its management: where are we now?

Ladha, A., Zhao, J., Epner, E. M., & Pu, J. J. (2019) · Experimental Hematology and Oncology · doi:10.1186/s40164-019-0126-0 · Cited by 44 · see citing works

THALIDOMIDE AND CONGENITAL ABNORMALITIES

Yang, T., Yang, T.-S., & Liang, H.-M. (1963) · The Lancet · doi:10.1016/s0140-6736(63)91347-3 · Cited by 44 · see citing works

Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today’s treat-to-target era

Zhang, L., Tai, Y., Ho, M., Qiu, L., & Anderson, K. C. (2017) · Experimental Hematology and Oncology · doi:10.1186/s40164-017-0081-6 · Cited by 42 · see citing works

Current development of chimeric antigen receptor T-cell therapy

Wang, J., Hu, Y., & Huang, H. (2018) · Stem Cell Investigation · doi:10.21037/sci.2018.11.05 · Cited by 32 · see citing works

Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)

Lonial, S., Amatangelo, M. D., Popat, R., Minnema, M. C., Zonder, J. A., Larsen, J. T., Oriol, A., Campagnaro, E. L., Rodríguez‐Otero, P., Badros, A. Z., et al. (2019) · Blood · doi:10.1182/blood-2019-124298 · Cited by 31 · see citing works

Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

Vitale, C., Falchi, L., ten Hacken, E., Gao, H., Shaim, H., Roosbroeck, K. V., Călin, G. A., O'Brien, S. M., Faderl, S., Wang, X., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2476 · Cited by 27 · see citing works

Iberdomide (CC-220) Has Synergistic Anti-Tumor and Immunostimulatory Activity Against Multiple Myeloma in Combination with Both Bortezomib and Dexamethasone, or in Combination with Daratumumab in Vitro

Amatangelo, M. D., Bjorklund, C. C., Kang, J., Polonskaia, A., Viswanatha, S., & Thakurta, A. (2018) · Blood · doi:10.1182/blood-2018-99-113383 · Cited by 26 · see citing works

Long‐term analysis of phase II studies of single‐agent lenalidomide in relapsed/refractory mantle cell lymphoma

Witzig, T. E., Zinzani, P. L., Habermann, T. M., Tuscano, J. M., Drach, J. W., Ramchandren, R., Beşışık, S. K., Takeshita, K., Bravo, M. C., Zhang, L., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24854 · Cited by 24 · see citing works

CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma

Cubillos‐Zapata, C., Córdoba, R., Ortiz, J. A., Arribas-Jiménez, C., Hernández-Jiménez, E., Toledano, V., Villaescusa, T., Moreno, V., & López‐Collazo, E. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1231290 · Cited by 23 · see citing works

Avadomide (CC-122), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma

Nastoupil, L. J., Bijou, F. D., Ribrag, V., Chávez, J. C., Witzig, T. E., Andorsky, D. J., Klein, L. M., Greenwald, D. R., Santoro, A., Corradini, P., et al. (2018) · Blood · doi:10.1182/blood-2018-99-114409 · Cited by 7 · see citing works

Avadomide (CC-122), a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Michot, J., Bouabdallah, R., Doorduijn, J. K., Vitolo, U., Kersten, M. J., Chiappella, A., Zinzani, P. L., Salles, G., Bijou, F. D., Sarmiento, R., et al. (2018) · Blood · doi:10.1182/blood-2018-99-110213 · Cited by 4 · see citing works

Advancing targeted protein degradation for cancer therapy

Dale, B., Cheng, M., Park, K., Kanıskan, H. Ü., Xiong, Y., & Jin, J. J. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00365-x · Cited by 671 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

Control of human toxoplasmosis

Smith, N. C., Goulart, C., Hayward, J. A., Kupz, A., Miller, C., & van Dooren, G. G. (2020) · International Journal for Parasitology · doi:10.1016/j.ijpara.2020.11.001 · Cited by 291 · see citing works

Prey for the Proteasome: Targeted Protein Degradation—A Medicinal Chemist's Perspective

Luh, L. M., Scheib, U., Juenemann, K., Wortmann, L., Brands, M., & Cromm, P. M. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202004310 · Cited by 200 · see citing works

Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress

Chu, Y., Zhou, X., & Wang, X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01097-z · Cited by 75 · see citing works

An overview of multiple myeloma: A monoclonal plasma cell malignancy’s diagnosis, management, and treatment modalities

Abduh, M. S. (2023) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2023.103920 · Cited by 65 · see citing works

Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

Hou, J., Ye, J. C., Pu, J. J., Liu, H., Ding, W., Zheng, H., & Liu, D. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01077-3 · Cited by 63 · see citing works

Clues to molecular glues

Geiger, T. M., Schäfer, S. C., Dreizler, J. K., Walz, M., & Hausch, F. (2021) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2021.100018 · Cited by 55 · see citing works

Targeting cereblon in hematologic malignancies

Fuchs, O. (2023) · Blood Reviews · doi:10.1016/j.blre.2022.100994 · Cited by 55 · see citing works

Machine Learning Modeling of Protein-Intrinsic Features Predicts Tractability of Targeted Protein Degradation

Zhang, W., Roy Burman, S. S., Chen, J., Donovan, K. A., Cao, Y., Shu, C., Zhang, B., Zeng, Z., Gu, S., Zhang, Y., et al. (2022) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.11.008 · Cited by 51 · see citing works

Novel promising benzoxazole/benzothiazole‐derived immunomodulatory agents: Design, synthesis, anticancer evaluation, and in silico ADMET analysis

Elkady, H., El‐Adl, K., Sakr, H. M., Abdelraheem, A. S., Eissa, S. I., & El‐Zahabi, M. A. (2023) · Archiv der Pharmazie · doi:10.1002/ardp.202300097 · Cited by 47 · see citing works

Targeted Protein Degradation: Principles and Applications of the Proteasome

Kim, Y., Kim, E.-K., Chey, Y., Song, M.-J., & Jang, H. H. (2023) · Cells · doi:10.3390/cells12141846 · Cited by 45 · see citing works

Cellular nanovesicles for therapeutic immunomodulation: A perspective on engineering strategies and new advances

Zhang, E., Phan, P., & Zhao, Z. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.08.020 · Cited by 42 · see citing works

Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them

Cippitelli, M., Stabile, H., Kosta, A., Petillo, S., Gismondi, A., Santoni, A., & Fionda, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031103 · Cited by 42 · see citing works

Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategy

Chen, S., Chen, Z., Lu, L., Zhao, Y., Zhou, R., Xie, Q., Shu, Y., Lin, J., Yu, X., & Wang, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115403 · Cited by 39 · see citing works

PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs

Maneiro, M., Vita, E. D., Conole, D., Kounde, C. S., Zhang, Q., & Tate, E. W. (2021) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2021.01.002 · Cited by 38 · see citing works

Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor

Liu, H., Mi, Q., Ding, X., Lin, C., Liu, L., Ren, C., Shen, S., Shao, Y., Chen, J., Zhou, Y., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114810 · Cited by 35 · see citing works

Key Considerations in Targeted Protein Degradation Drug Discovery and Development

Qin, L., Dai, H., & Wang, J. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.934337 · Cited by 34 · see citing works

Targeting N-Myc in neuroblastoma with selective Aurora kinase A degraders

Tang, J., Moorthy, R., Hirsch, L. E., Demir, Ö., Baker, Z. D., Naumann, J. A., Jones, K. F. M., Grillo, M. J., Haefner, E. S., Shi, K., et al. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2024.12.006 · Cited by 33 · see citing works

Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models

Lim, Y. S., Yoo, S.-M., Patil, V., Kim, H. W., Kim, H.-H., Suh, B., Park, J. Y., Jeong, N.-R., Park, C. H., Ryu, J. H., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008121 · Cited by 32 · see citing works

Targeted Protein Degradation: Clinical Advances in the Field of Oncology

Salama, A. K. A. A., Trkulja, M. V., Casanova, E., & Uras, I. Z. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315440 · Cited by 32 · see citing works

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Su, C. T., & Ye, J. C. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01109-y · Cited by 30 · see citing works

Progress of small molecules for targeted protein degradation: PROTACs and other technologies

Zhao, H., Xin, M., & Zhang, S. (2023) · Drug Development Research · doi:10.1002/ddr.22026 · Cited by 31 · see citing works

FAK PROTAC Inhibits Ovarian Tumor Growth and Metastasis by Disrupting Kinase Dependent and Independent Pathways

Huo, X., Zhang, W., Zhao, G., Chen, Z., Dong, P., Watari, H., Narayanan, R., Tillmanns, T. D., Pfeffer, L. M., & Yue, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.851065 · Cited by 27 · see citing works

Development of Novel Silicon-Based Hydrophobic Tags (SiHyT) for Targeted Proteins Degradation

Lan, M., Zhang, K., Huang, Z., Guo, Y., Liu, N., Chen, J., Wang, X., Liu, Y., Li, M., Li, J., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02273 · Cited by 26 · see citing works

Bayesian optimization for ternary complex prediction (BOTCP)

Rao, A., Tunjic, T. M., Brunsteiner, M., Müller, M., Fooladi, H., Gasbarri, C., & Weber, N. (2023) · Artificial Intelligence in the Life Sciences · doi:10.1016/j.ailsci.2023.100072 · Cited by 25 · see citing works

Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation

Li, P., Hu, X., Fan, Z., Sun, S., Ran, Q., Wei, T., Wei, P., Jiang, Q., Yan, J. W., Yang, N., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01592-z · Cited by 24 · see citing works

Lenalidomide bypasses CD28 co-stimulation to reinstate PD-1 immunotherapy by activating Notch signaling

Geng, C., Chen, J., Song, T., Jung, J. H., Long, M., Song, M., Ji, T., Min, B. S., Lee, J. G., Peng, B., et al. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.05.012 · Cited by 21 · see citing works

The Role of Specialized Pro-Resolving Lipid Mediators in Inflammation-Induced Carcinogenesis

Torres, W., Pérez, J. L., Diaz, M. P., D’Marco, L., Checa-Ros, A., Carrasquero, R., Angarita, L., Gómez, Y., Chacín, M., Ramírez, P., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612623 · Cited by 21 · see citing works

Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs)

Tomaselli, D., Mautone, N., Mai, A., & Rotili, D. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112750 · Cited by 21 · see citing works

Immunomodulatory Drugs in Acute Myeloid Leukemia Treatment

Piccolomo, A., Schifone, C. P., Strafella, V., Specchia, G., Musto, P., & Albano, F. (2020) · Cancers · doi:10.3390/cancers12092528 · Cited by 20 · see citing works

PROTAC-mediated CDK degradation differentially impacts cancer cell cycles due to heterogeneity in kinase dependencies

Kumarasamy, V. M., Gao, Z., Zhao, B., Jiang, B., Rubin, S. M., Burgess, K., Witkiewicz, A. K., & Knudsen, E. S. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02399-4 · Cited by 20 · see citing works

BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of Ph+ leukemias?

Cruz-Rodríguez, N., Tang, H., Bateman, B., Tang, W., & Deininger, M. W. (2024) · Leukemia · doi:10.1038/s41375-024-02365-w · Cited by 19 · see citing works

T lymphocyte plasticity in chronic inflammatory diseases: The emerging role of the Ikaros family as a key Th17-Treg switch

Ramón-Vázquez, A., Flood, P. F., Cashman, T. L., Patil, P., & Ghosh, S. K. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103735 · Cited by 18 · see citing works

Key regulators of sensitivity to immunomodulatory drugs in cancer treatment

Wang, S., Li, Z., & Gao, S. (2021) · Biomarker Research · doi:10.1186/s40364-021-00297-6 · Cited by 17 · see citing works

Ikaros Proteins in Tumor: Current Perspectives and New Developments

Xia, R., Cheng, Y., Han, X., Wei, Y., & Wei, X. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.788440 · Cited by 15 · see citing works

Immunomodulation and anticancer evaluation of quinazoline-based thalidomide analogs: Design, synthesis, docking, and dynamic simulation

Abdallah, A. E., Eissa, I. H., Mehany, A. B. M., Sakr, H. M., Sakr, T. M., Metwaly, K. H., Celik, I., El‐Adl, K., & El‐Zahabi, M. A. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.139082 · Cited by 14 · see citing works

Cereblon: promise and challenges for combating human diseases

Kim, H. K., Seol, J. E., Ahn, S. W., Jeon, S., Park, C., & Han, J. (2021) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-021-02624-0 · Cited by 14 · see citing works

Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma

Patel, T. H., van Rhee, F., & Hadidi, S. A. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.06.004 · Cited by 13 · see citing works

Targeted Protein Degradation: An Important Tool for Drug Discovery for “Undruggable” Tumor Transcription Factors

Dai, M., Sridhar, R., Li, R., Tan, R., Yan, K., Fan, G., & Liu, M. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221095950 · Cited by 13 · see citing works

Discovery of Rigid Linker-Based IRAK4 PROTACs with Improved Metabolic Stability for the Treatment of Inflammatory Diseases

Fan, Y., Ma, R., Njobvu, K. M., Wang, Y., Ren, Y., Fu, R., Zhang, C., Liu, F., Jiang, Z., Rao, Y., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01620 · Cited by 11 · see citing works

PPAR agonists attenuate lenalidomide's anti-myeloma activity in vitro and in vivo

Sha, Y., Wu, J., Paul, B. A., Zhao, Y., Mathews, P., Li, Z., Norris, J., Wang, E., McDonnell, D. P., & Kang, Y. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215832 · Cited by 11 · see citing works

Lower BCL11B expression is associated with adverse clinical outcome for patients with myelodysplastic syndrome

Huang, X., Chen, C., Zhong, M., Geng, S., Zhao, Y., Li, M., Deng, C., Zeng, L., Wu, P., Lu, Z., et al. (2021) · Biomarker Research · doi:10.1186/s40364-021-00302-y · Cited by 10 · see citing works

Exploring the binding mechanism of Pomalidomide drug with CT-DNA: Insights from multi-spectroscopic, molecular docking and simulation studies

Pavithra, K., Priyadharshini, R. D., Vennila, K. N., & Elango, K. P. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.137547 · Cited by 10 · see citing works

Thalidomide-induced limb malformations: an update and reevaluation

Collins, M. D., & Scott, W. J. (2025) · Archives of Toxicology · doi:10.1007/s00204-024-03930-z · Cited by 10 · see citing works

Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies

Abbiati, R. A., Pourdehnad, M., Carrancio, S., Pierce, D. W., Kasibhatla, S., McConnell, M. T., Trotter, M. W. B., Loos, R., Santini, C. C., & Ratushny, A. V. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00623-8 · Cited by 9 · see citing works

The Casein kinase 1α agonist pyrvinium attenuates Wnt-mediated CK1α degradation via interaction with the E3 ubiquitin ligase component Cereblon

Shen, C., Nayak, A., Neitzel, L. R., Yang, F., Li, B., Williams, C. H., Hong, C. C., Ahmed, Y. F., Lee, E. N., & Robbins, D. J. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102227 · Cited by 9 · see citing works

Advances in the pharmacotherapeutic options for primary nodal peripheral T-cell lymphoma

Wolska, A., Smolewski, P., & Robak, T. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1882997 · Cited by 9 · see citing works

Controlling CRISPR-Cas9 genome editing in human cells using a molecular glue degrader

Khajanchi, N., Patel, V., Dua, R., Kabra, M., Pattnaik, B. R., & Saha, K. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102640 · Cited by 8 · see citing works

Discovery of Novel Potent Triple IKZF1/2/3 Degraders for the Treatment of Hematological Cancers

Wei, T., Sun, S., Hu, X., Wei, P., Fan, Z., Yan, J. W., Wang, Y., Qi, Z., Jia, C., Mao, Y., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01086 · Cited by 8 · see citing works

Application of proteolysis targeting chimeric (PROTAC) technology in protein regulation and drug development

He, Y., Liao, T., Wang, X., Xiao, Q. H., Wang, H., He, R. R., Zhao, C., Tian, X., Gao, Q., & Hao, L. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108846 · Cited by 8 · see citing works

Drugging the undruggable: Chemical and biological insights into molecular glues in the pipeline

Metwally, K. A., Yahya, G., & Abo-Dya, N. E. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118132 · Cited by 8 · see citing works

Modular PROTAC/IMiD Bifunctional Molecule Design for the Degradation of Synergistic Targets in the Treatment of Lymphoma

Jin, Y., Liao, X., Zhang, J., Duan, H., Xu, R., Luo, X., Yu, X., Li, B., Wang, J., Li, X., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01159 · Cited by 8 · see citing works

Novel IKZF3 transcriptomic signature correlates with positive outcomes of skin cutaneous melanoma: A pan-cancer analysis

Yang, L.-K., Lin, C.-X., Li, S., Liang, J.-J., Xiao, L., Xie, G., Liu, H., & Liao, X. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1036402 · Cited by 8 · see citing works

Discovery of novel benzosultam CRBN ligands

Park, H., Raikar, S. S., Kim, Y., Chae, C. H., Cho, Y., & Kim, P. (2025) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.12921 · Cited by 7 · see citing works

Nonclinical teratogenicity safety assessment of CRBN-engaging targeted protein degraders: Points to consider

Loberg, L. I., Proctor, W. R., Burdick, A. D., Cauvin, A. J., DeLise, A. M., Hemkens, M. D., Hohlbaum, A. M., Hukkanen, R. R., Sedgwick, A., Shuey, D. L., et al. (2025) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2025.105793 · Cited by 7 · see citing works

Beute für das Proteasom: Gezielter Proteinabbau aus medizinalchemischer Perspektive

Luh, L. M., Scheib, U., Juenemann, K., Wortmann, L., Brands, M., & Cromm, P. M. (2020) · Angewandte Chemie · doi:10.1002/ange.202004310 · Cited by 7 · see citing works

Adherence to thalidomide in patients with multiple myeloma: A cross-sectional study in a Brazilian metropolis

Silveira, L. P., de Pádua, C. A. M., Drummond, P. L. D. M., Malta, J. S., dos Santos, R. M. M., Costa, N. L., Machado, T. R. L., Hauck, L. M., & Reis, A. M. M. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155221993528 · Cited by 7 · see citing works

Proteasomal Degradation of Zn-Dependent Hdacs: The E3-Ligases Implicated and the Designed Protacs That Enable Degradation

Márquez-Cantudo, L., Ramos, A., Coderch, C., & de Pascual‐Teresa, B. (2021) · Molecules · doi:10.3390/molecules26185606 · Cited by 7 · see citing works

Design and Evaluation of PROTACs Targeting Acyl Protein Thioesterase 1

Carvalho, L. A. R., Sousa, B. B., Zaidman, D., Kiely‐Collins, H., & Bernardes, G. J. L. (2024) · ChemBioChem · doi:10.1002/cbic.202300736 · Cited by 6 · see citing works

Navigating The Deuteration Landscape: Innovations, Challenges, and Clinical Potential of Deuterioindoles

Zhang, L., Zhang, S., Zhang, Y., Liu, B., Li, X., & Han, B. (2024) · ChemBioChem · doi:10.1002/cbic.202400837 · Cited by 5 · see citing works

Targeted protein degradation in autoimmune diseases: from mechanisms to therapeutic breakthroughs

Song, Y., Zhou, B., Long, J., & Peng, Y. (2025) · Journal of Autoimmunity · doi:10.1016/j.jaut.2025.103475 · Cited by 5 · see citing works

Computational investigations of indanedione and indanone derivatives in drug discovery: Indanone derivatives inhibits cereblon, an E3 ubiquitin ligase component

Nayek, U., Ahamed, S. I. B., Hussain, U. H. M., Unnikrishnan, M. K., & Salam, A. A. A. (2022) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2022.107776 · Cited by 5 · see citing works

Discovery of a new class of potent pyrrolo[3,4-c]quinoline-1,3-diones based inhibitors of human dihydroorotate dehydrogenase: Synthesis, pharmacological and toxicological evaluation

Dimitrijević, M. G., Roschger, C., Lang, K., Zierer, A. F., Paunović, M. G., Obradović, A. D., Matić, M. M., Pocrnić, M., Galić, N., Ćirić, A., et al. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107359 · Cited by 5 · see citing works

Decoding multicomponent crosstalk: integrated pharmacodynamic‒pharmacokinetic network of sour jujube seed

Wu, Y., Sun, L., Ma, Y., Wu, L., Niu, W., Li, J., Feng, Q.-M., Wang, S., Niu, H., Bai, Q., et al. (2025) · Chinese Medicine · doi:10.1186/s13020-025-01265-0 · Cited by 4 · see citing works

Design, Synthesis, and Anti-inflammatory Activity Evaluation for Hydrazide-Based HDAC6 Targeted Protein Degraders

Sun, S., Yue, K., Liu, E., Sheng, D., Chen, Y., Li, T., Shen, A., Jia, G., Jiang, Y., & Li, X. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02554 · Cited by 3 · see citing works

Preclinical Studies of PROTACs in Hematological Malignancies

Fuchs, O., & Bokorová, R. (2021) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x21666210308111546 · Cited by 3 · see citing works

New Therapeutic Modalities: Transforming Drug Discovery and Development

Blanco, M.-J. (2023) · Springer eBooks · doi:10.1007/978-3-030-73317-9_135-1 · Cited by 3 · see citing works

New Therapeutic Modalities: Transforming Drug Discovery and Development

Blanco, M.-J. (2024) · Springer eBooks · doi:10.1007/978-3-031-35529-5_135 · Cited by 2 · see citing works

Brazilian red propolis synergistically with imipenem modulates immunological parameters and the bactericidal activity of human monocytes against methicillin-resistant Staphylococcus aureus (MRSA)

Ripari, N., Honorio, M. D. S., Sartori, A. A., de Oliveira, L. R. C., Bastos, J. K., & Sforcin, J. M. (2024) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgae135 · Cited by 2 · see citing works

Emerging pharmacology of targeted protein degraders

Barghout, S. H., & Eldeeb, M. A. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103694 · Cited by 2 · see citing works

Innovative Trials and New Opportunities in SLE

Chaichian, Y., & Wallace, D. J. (2021) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2021.04.010 · Cited by 2 · see citing works

Synthetic and Medicinal Chemistry Perspectives on Cereblon‐Binding Molecular Glue Degraders: Recent Advances and Emerging Trends

Won, H.-J., Baek, S. M., Lee, M. H., Park, J. H., Shin, J., Yang, Y., Jang, Y. H., Inn, K., & Kim, N. (2026) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202501208 · Cited by 1 · see citing works

Advances in monitoring and therapy from minimal residual disease to CAR-T cells in multiple myeloma and precursor disorders

El‐Sehrawy, A. A. M. A., Oriquat, G., Saidov, S., Ruzikulov, U., Shakhmurova, G., Jbl, B. J., Singhal, D., & Shefali (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.121066 · Cited by 1 · see citing works

Proteolysis-targeting chimeras (PROTACs) as novel biotechnology for cancer therapy

Fuchs, O. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90042-3.15001-7 · Cited by 1 · see citing works

Ligand Design for Cereblon Based Immunomodulatory Therapy

Kargbo, R. B. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00214 · Cited by 1 · see citing works

A New IMiD for Systemic Lupus Erythematosus — Tempering Our Excitement

Costenbader, K. H. (2022) · New England Journal of Medicine · doi:10.1056/nejme2201329 · Cited by 1 · see citing works

Helminth Induced Immunomodulation against Metainflammation and Insulin Resistance

Aravindhan, V., & Sibi, J. M. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98230

Construction of PD1/CD28 Fusion Receptor Enhances Anti-Tumor Ability of c-Met CAR-T in Gastric CancerPreprint

Chen, C., Gu, Y., Zhang, Z., Zhang, Y., He, Y.-D., Tang, F., Liu, H., & Li, Y. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3738093

Orally bioavailable Bruton’s tyrosine kinase proteolysis-targeting chimeras active against wild-type and C481 mutant BTKs in murine hematology modelsPreprint

Lim, Y. S., Yoo, S.-M., Patil, V., Kim, H. W., Kim, H.-H., Suh, B., Park, J. Y., Jeong, N.-R., Park, C. H., Ryu, J. H., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1528349/v1

Technological Mapping of Plant-Derived Immunomodulator Drugs: A Patent-Guided Overview about Species and its Main Compounds

Neto, J. D. B. V., Silva, M. F. S., Marques, L. G. A., Paier, C. R. K., Ferreira, P. M. P., & Pessoa, C. (2022) · Springer eBooks · doi:10.1007/978-981-16-8117-2_18

Síndrome Mielodisplásico por deleción del brazo largo del cromosoma 5. Reporte de caso y revisión de la literatura – myelodysysplasic

Sánchez, A. F. R., & Espinoza, E. A. R. (2023) · Brazilian Journal of Health Review · doi:10.34119/bjhrv6n2-039

Heterobifunctional Degraders for the Treatment of Lymphoid Malignancies

Gollerkeri, A. M., Gollob, A. J., & Mainolfi, N. (2023) · doi:10.1002/9781119819950.ch26

A Review of the Immunomodulatory Activity of Novel Drug Iberdomide (CC-220) for Multiple Myeloma

Cardenas, S. A., Cosio, C. J., Lee, S. J., Domingo, F. J., Gido, D. R., Lim, A. J., & Abiso-Padilla, J. (2023) · International Journal of Research Publication and Reviews · doi:10.55248/gengpi.4.1223.123549

Targeted protein degradation using thalidomide and its derivatives

Yamanaka, S. (2024) · Translational and Regulatory Sciences · doi:10.33611/trs.2024-007

Novel Immunotherapeutic Approaches for Cancer Therapy

Vishwakarma, K., Shrivastav, M., Kausar, A., Mishra, S., Anitha, K., Shrivastav, A., Kesharwani, S., & Verma, A. K. (2024) · Springer eBooks · doi:10.1007/978-981-97-7022-9_3

Additional file 5 of Lower BCL11B expression is associated with adverse clinical outcome for patients with myelodysplastic syndrome

Huang, X., Chen, C., Zhong, M., Geng, S., Zhao, Y., LI, M., Deng, C., Zeng, L., Wu, P., Lu, Z., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14767180

Additional file 4 of Lower BCL11B expression is associated with adverse clinical outcome for patients with myelodysplastic syndrome

Huang, X., Chen, C., Zhong, M., Geng, S., Zhao, Y., LI, M., Deng, C., Zeng, L., Wu, P., Lu, Z., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14767177

Additional file 1 of Lower BCL11B expression is associated with adverse clinical outcome for patients with myelodysplastic syndrome

Huang, X., Chen, C., Zhong, M., Geng, S., Zhao, Y., LI, M., Deng, C., Zeng, L., Wu, P., Lu, Z., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14767168

Additional file 2 of Lower BCL11B expression is associated with adverse clinical outcome for patients with myelodysplastic syndrome

Huang, X., Chen, C., Zhong, M., Geng, S., Zhao, Y., LI, M., Deng, C., Zeng, L., Wu, P., Lu, Z., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14767171

Additional file 3 of Lower BCL11B expression is associated with adverse clinical outcome for patients with myelodysplastic syndrome

Huang, X., Chen, C., Zhong, M., Geng, S., Zhao, Y., LI, M., Deng, C., Zeng, L., Wu, P., Lu, Z., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14767174

Targeting enzymes through PROTAC-mediated degradation: When is a PROTAC better than a small molecule inhibitor?

Gerritz, S. W., Campbell, A.-M., Klug, D. M., & Sherman, D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00074-1

Therapeutic Horizon in Multiple Myeloma: Analysis of the Emerging Landscape of Clinical Trials

Alacoque, M., de Pádua, C. A. M., Drummond, P. L. D. M., Malta, J. S., & Reis, A. M. M. (2026) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-026-00971-7

IMMUNOSTIMULANT EFFECTS OF PROPOLIS: A study of cytokine production

Putri, M. S. D., Fitriani, H., Syukri, Y., & Ramadani, A. P. (2026) · Jurnal Ilmiah Ibnu Sina (JIIS) Ilmu Farmasi dan Kesehatan · doi:10.36387/jiis.v11i1.2926

BindingDB Entry 50018808: Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor.

BindingDB (2024) · UC San Diego · doi:10.7270/q27p93nv

BindingDB Entry 50019287: Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategy.

BindingDB (2024) · UC San Diego · doi:10.7270/q2dv1q8m

BindingDB Entry 50018350: Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs).

BindingDB (2024) · UC San Diego · doi:10.7270/q2x352pq

Immunomodulatory drugs in the treatment of multiple myeloma

Abe, Y., & Ishida, T. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz083 · Cited by 30 · see citing works

Mechanisms of action of immunomodulatory drugs — from teratogenicity to treatment of multiple myeloma

Семочкин, С. В. (2022) · Гематология и трансфузиология · doi:10.35754/0234-5730-2022-67-2-240-260 · Cited by 12 · see citing works

Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation

Yamanaka, S., Furihata, H., Yanagihara, Y., Taya, A., Nagasaka, T., Usui, M., Nagaoka, K., Shoya, Y., Nishino, K., Yoshida, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40385-9 · Cited by 73 · see citing works

Discovery of the target for immunomodulatory drugs (IMiDs).

Ito, T., Ando, H., & Handa, H. (2016) · PubMed · doi:10.11406/rinketsu.57.556 · Cited by 6 · see citing works

Novel mechanisms of action for immunomodulatory drugs (IMiDs) against multiple myeloma: from a tragedy to a therapy

Dai, Y., & Jin, F. (2016) · International Journal of Hematology and Therapy · doi:10.15436/2381-1404.15.008 · Cited by 2 · see citing works